Hiroshi Hasuo1, Shiro Tomiyasu1, Minoru Hojo1, Toru Fujigaki2, Makoto Fukusaki3, Koji Sumikawa1. 1. Department of Anesthesiology, Nagasaki University School of Medicine, 1-7-1 Sakamoto, 852-8501, Nagasaki, Japan. 2. Department of Anesthesiology, Oita Prefectural Hospital, 476 Bunyou, 870-0855, Oita, Japan. 3. Department of Anesthesiology, Nagasaki Rousai Hospital, 2-12-5 Setogosi, 857-0134, Sasebo, Japan.
Abstract
PURPOSE: We investigated the effect of a new ultrashort-acting β-blocker, ONO-1101, on hemodynamic responses to isoflurane inhalation and tracheal intubation. METHODS:Fifty-four ASA PS 1 or 2 patients were randomly allocated to receive either ONO-1101, 0.04 mg·kg-1·min-1, or saline prior to tracheal intubation. Anesthesia was induced with thiamylal, 4 mg·kg-1, and vecuronium, 0.15 mg·kg-1. Tracheal intubation was carried out after 3 min controlled mask ventilation with 66% N2O and 3% inspired isoflurane in oxygen. Heart rate and blood pressure were continuously recorded from the start of induction until 5 min after intubation. Plasma concentrations of catecholamines were measured before induction, 3 min after initiating inhalation of isoflurane, and 1 min after tracheal intubation. RESULTS: Significant increases in heart rate occurred in both groups in response to isoflurane inhalation and tracheal intubation, but the magnitude of the increase was significantly less in the ONO-1101 group. Blood pressure increased after tracheal intubation in the saline group but remained unchanged in the ONO-1101 group. Plasma concentrations of norepinephrine increased after induction and intubation in both groups, with no significant difference between the groups. CONCLUSION:ONO-1101 infusion is effective for the attenuation of hemodynamic responses to isoflurane inhalation and tracheal intubation.
RCT Entities:
PURPOSE: We investigated the effect of a new ultrashort-acting β-blocker, ONO-1101, on hemodynamic responses to isoflurane inhalation and tracheal intubation. METHODS: Fifty-four ASA PS 1 or 2 patients were randomly allocated to receive either ONO-1101, 0.04 mg·kg-1·min-1, or saline prior to tracheal intubation. Anesthesia was induced with thiamylal, 4 mg·kg-1, and vecuronium, 0.15 mg·kg-1. Tracheal intubation was carried out after 3 min controlled mask ventilation with 66% N2O and 3% inspired isoflurane in oxygen. Heart rate and blood pressure were continuously recorded from the start of induction until 5 min after intubation. Plasma concentrations of catecholamines were measured before induction, 3 min after initiating inhalation of isoflurane, and 1 min after tracheal intubation. RESULTS: Significant increases in heart rate occurred in both groups in response to isoflurane inhalation and tracheal intubation, but the magnitude of the increase was significantly less in the ONO-1101 group. Blood pressure increased after tracheal intubation in the saline group but remained unchanged in the ONO-1101 group. Plasma concentrations of norepinephrine increased after induction and intubation in both groups, with no significant difference between the groups. CONCLUSION:ONO-1101 infusion is effective for the attenuation of hemodynamic responses to isoflurane inhalation and tracheal intubation.
Authors: S Iguchi; H Iwamura; M Nishizaki; A Hayashi; K Senokuchi; K Kobayashi; K Sakaki; K Hachiya; Y Ichioka; M Kawamura Journal: Chem Pharm Bull (Tokyo) Date: 1992-06 Impact factor: 1.645